Bitter medicine. New regulations aim to address the dearth of clinical safety trials for drugs used in children

Journal Title: EMBO Reports - Year 2008, Vol 9, Issue 6

Abstract

Authors and Affiliations

Mark Greener

Keywords

Related Articles

The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes

The positive transcription elongation factor b (P-TEFb) is a heterodimeric complex composed of cyclin-dependent kinase 9 and its regulator cyclin T1/2. It stimulates transcription elongation by phosphorylation of serine...

Down to atomic-scale intracellular water dynamics

Water constitutes the intracellular matrix in which biological molecules interact. Understanding its dynamic state is a main scientific challenge, which continues to provoke controversy after more than 50 years of study....

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

The embryonic programme ‘epithelial–mesenchymal transition' (EMT) is thought to promote malignant tumour progression. The transcriptional repressor zinc-finger E-box binding homeobox 1 (ZEB1) is a crucial...

NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33ING1b

The tumour suppressor p33ING1b (ING1b for inhibitor of growth family, member 1b) is important in cellular stress responses, including cell-cycle arrest, apoptosis, chromatin remodelling and DNA repair; however, its degra...

Download PDF file
  • EP ID EP679936
  • DOI  10.1038/embor.2008.95
  • Views 31
  • Downloads 0

How To Cite

Mark Greener (2008). Bitter medicine. New regulations aim to address the dearth of clinical safety trials for drugs used in children. EMBO Reports, 9(6), -. https://europub.co.uk/articles/-A-679936